# Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients

> **NCT04898270** · PHASE4 · COMPLETED · sponsor: **Taichung Veterans General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Schizophrenia; Psychosis
- Metabolic Syndrome
- Flupentixol
- Antipsychotic Agents
- Central Nervous System Diseases
- Clinical Therapy
- Olanzapine
- Quetiapine

## Interventions

- **DRUG:** Flupentixol
- **DRUG:** Multi-acting receptor-targeted antipsychotics (MARTAs)

## Key facts

- **NCT ID:** NCT04898270
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-04-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898270, "Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04898270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*